Published in Clin Trials on April 30, 2012
Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol (2013) 1.15
The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79
A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics (2015) 0.78
Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy. J Thorac Dis (2016) 0.75
The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. PLoS One (2014) 0.75
A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics (2015) 0.75
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med (2004) 5.47
Comparison of "B" readers' interpretations of chest radiographs for asbestos related changes. Acad Radiol (2004) 4.71
The accuracy of surrogate decision makers: a systematic review. Arch Intern Med (2006) 4.17
Development in infants with autism spectrum disorders: a prospective study. J Child Psychol Psychiatry (2006) 3.54
Social and communication development in toddlers with early and later diagnosis of autism spectrum disorders. Arch Gen Psychiatry (2007) 3.29
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Endoscopic cold incision, balloon dilation, mitomycin C application, and steroid injection for adult laryngotracheal stenosis. Laryngoscope (2012) 2.03
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis (2007) 1.91
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res (2009) 1.85
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
Response to joint attention in toddlers at risk for autism spectrum disorder: a prospective study. J Autism Dev Disord (2007) 1.65
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol (2011) 1.61
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res (2006) 1.58
Prevalence and determinants of physician bedside rationing: data from Europe. J Gen Intern Med (2006) 1.57
Hidden Markov models for zero-inflated Poisson counts with an application to substance use. Stat Med (2011) 1.56
Using endobronchial ultrasound features to predict lymph node metastasis in patients with lung cancer. Chest (2011) 1.54
ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett (2010) 1.50
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res (2008) 1.43
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology (2010) 1.43
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst (2007) 1.41
Ductal access for prevention and therapy of mammary tumors. Cancer Res (2006) 1.38
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res (2004) 1.35
Does it pay to pay? A randomized trial of prepaid financial incentives and lottery incentives in surveys of nonphysician healthcare professionals. Nurs Res (2005) 1.32
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol (2008) 1.30
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology (2011) 1.21
Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther (2006) 1.19
A LATENT FACTOR MODEL FOR SPATIAL DATA WITH INFORMATIVE MISSINGNESS. Ann Appl Stat (2010) 1.19
Association models for clustered data with binary and continuous responses. Biometrics (2009) 1.17
Oral health knowledge and behavior among adults with diabetes. Diabetes Res Clin Pract (2009) 1.17
A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One (2011) 1.17
Initial monotherapy and combination therapy and hypertension control the first year. Hypertension (2012) 1.15
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res (2010) 1.15
Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci (2005) 1.14
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant (2006) 1.12
Comparison of aphakic refraction formulas for secondary in-the-bag intraocular lens power estimation in children. J AAPOS (2011) 1.12
Linear and nonlinear mixed-effects models for censored HIV viral loads using normal/independent distributions. Biometrics (2011) 1.11
(S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis (2013) 1.10
Predictors of cessation pharmacotherapy use among black and non-Hispanic white smokers. Nicotine Tob Res (2011) 1.10
Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. Proc Natl Acad Sci U S A (2004) 1.09
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab (2012) 1.08
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control (2009) 1.08
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer (2007) 1.07
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther (2004) 1.06
Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol (2007) 1.05
Likelihood methods for binary responses of present components in a cluster. Biometrics (2010) 1.03
Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res (2008) 1.01
Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders. Drug Alcohol Depend (2011) 1.00
Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer (2010) 1.00
Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res (2008) 0.99
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant (2006) 0.99
Effect of DNA methylation on identification of aggressive prostate cancer. Urology (2008) 0.98
Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. Stat Med (2011) 0.98
Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer (2009) 0.98
Heteroscedastic nonlinear regression models based on scale mixtures of skew-normal distributions. Stat Probab Lett (2011) 0.97
Non-treatment laboratory stress- and cue-reactivity studies are associated with decreased substance use among drug-dependent individuals. Drug Alcohol Depend (2009) 0.97
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology (2007) 0.97
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood (2014) 0.96
Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol (2007) 0.96
Exploration of dimensionality and psychometric properties of the Pittsburgh Sleep Quality Index in cases with temporomandibular disorders. Health Qual Life Outcomes (2014) 0.95
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant (2005) 0.94
Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res (2006) 0.94
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors. Hum Mol Genet (2005) 0.94
High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Ann Epidemiol (2012) 0.94
Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina. Prog Community Health Partnersh (2012) 0.94
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res (2008) 0.93
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther (2007) 0.93
Adolescent nondaily smokers: favorable views of tobacco yet receptive to cessation. Nicotine Tob Res (2009) 0.93
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response. Clin Cancer Res (2011) 0.91
Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg (2007) 0.91
Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord (2009) 0.91
Evaluation of a nutrition education intervention for women residents of Washington, DC, public housing communities. Health Educ Res (2006) 0.91
Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement Groups. Int J Radiat Oncol Biol Phys (2010) 0.91
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol (2010) 0.91
Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Res (2013) 0.90
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) (2011) 0.90
Modified test statistics by inter-voxel variance shrinkage with an application to f MRI. Biostatistics (2008) 0.90
The pH taxis of an intelligent catalytic microbot. Small (2013) 0.90
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica (2012) 0.90
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol (2009) 0.89
The risk of dying from lung cancer by race: a prospective cohort study in a biracial cohort in Charleston, South Carolina. Ann Epidemiol (2009) 0.89
Concordance of cancer patients' function, symptoms, and supportive care needs. Qual Life Res (2009) 0.89
A nonparametric spatial model for periodontal data with non-random missingness. J Am Stat Assoc (2013) 0.89
Ethical conflict in nurse practitioners and physician assistants in managed care. Nurs Res (2006) 0.89
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant (2007) 0.88
Bridging conditional and marginal inference for spatially referenced binary data. Biometrics (2013) 0.87
Dynamics of tissue shrinkage during ablative temperature exposures. Physiol Meas (2013) 0.87
A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg (2008) 0.86